scholarly journals High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

2015 ◽  
pp. 117 ◽  
Author(s):  
Kuaile Zhao ◽  
Chunyu Wang ◽  
Xiaolong Fu ◽  
Xuwei Cai ◽  
Xianghua Wu ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
High Dose

Utility of esophageal stenting for esophageal cancer patients with dysphagia undergoing neoadjuvant therapy.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 105-105 ◽  
Author(s):  
R. E. Brown ◽  
C. R. St. Hill ◽  
M. M. Harkenrider ◽  
S. Ellis ◽  
V. R. Sharma ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Symptom Relief ◽  
High Dose ◽  
Jejunostomy Tube ◽  
Resectable Esophageal ◽  
Prospective Phase ◽  
Esophageal Stenting

105 Background: For esophageal cancer patients with dysphagia, symptom relief and maintenance of nutrition remain significant barriers to completion of neoadjuvant therapy (NAT). We hypothesized that esophageal stenting would allow for successful delivery of planned NAT, with improvement in quality of life (QOL) and maintenance of nutrition. Methods: A multi-institution prospective phase II clinical trial examined esophageal cancer patients with dysphagia undergoing NAT. All had a self-expanding polymer esophageal stent (ES) placed at initiation of NAT. Individual chemotherapy and RT regimens were determined via multidisciplinary collaboration. Results: 32 patients were enrolled with dysphagia and potentially resectable esophageal cancers. All had ES placement prior to NAT. Two patients had stent migrations that required replacement. There were no ulcerations or perforations. Significant QOL improvements were noted within a week after ES placement, which persisted throughout NAT. NAT with chemo + RT was planned in 17 patients, of which 12 (71%) received planned dosing. NAT with chemotherapy alone was planned in 15 patients, of which 10 (67%) received planned dosing. Chemotherapy was most commonly 5FU/cisplatin based. 3D conformal RT with high dose photons was used most frequently, with a mean of 97% of the planned RT dose delivered. Among all patients, alterations (n=5, 16%) or cessation (n=5, 16%) of planned NAT regimens were required for treatment-related toxicity or disease progression. One patient required a jejunostomy tube for nutritional maintenance. Conclusions: Esophageal stenting is an effective method of improving QOL and relieving symptoms that allows for successful completion of NAT, with maintenance of performance and nutritional status. [Table: see text]

scholarly journals 92: Radiation Dose to Organs At Risk After High Dose Rate Brachytherapy for Esophageal Cancer Patients

2020 ◽  
Vol 150 ◽  
pp. S41
Author(s):  
Sahar Darvish-Molla ◽  
Emilia Timotin ◽  
Jack Skoczny ◽  
Thomas Farrell ◽  
Ranjan K. Sur
Keyword(s):  
At Risk ◽  
Esophageal Cancer ◽  
Radiation Dose ◽  
Dose Rate ◽  
Cancer Patients ◽  
Organs At Risk ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy

Self-expandable Metallic Stent Insertion for Nonresectable Esophageal Cancer Patients.

2001 ◽  
Vol 52 (2) ◽  
pp. 75-81
Author(s):  
Hideo Shimada ◽  
Osamu Chino ◽  
Takayuki Nishi ◽  
Hikaru Tanaka ◽  
Yoshifumi Kise ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Stent Insertion ◽  
Metallic Stent ◽  
Expandable Metallic Stent
Sign in / Sign up

Export Citation Format

Share Document